OTC Markets OTCQX - Delayed Quote USD

Orgenesis Inc. (ORGS)

2.1700

0.0000

(0.00%)

At close: 1:44:07 PM EDT

Orgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening its Regenerative Medicine Portfolio with Spinal Cord Injury Therapies

Strategic Acquisition Designed to Expand Access to Cost-Effective, Scalable Regenerative Medicine Treatments GERMANTOWN, MD / ACCESS Newswire / March 6, 2025 / Orgenesis Inc. (OTCQX:ORGS) ("Orgenesis" or the "Company"), a global biotech company working ...

ACCESS Newswire last month

ORGS
0.00%
Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings

Orgenesis Inc. (OTCQX:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today announced that it has concluded ...

ACCESS Newswire 3 months ago

ORGS
0.00%
Orgenesis Provides Third Quarter 2024 Business Update

GERMANTOWN, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (OTCQX: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today provided a business update for the third quarter ended September 30, 2024. Vered Caplan, CEO of Orgenesis, stated, “Orgenesis is making significant progress in redefining accessibility to cell and gene therapies through our decentra

GlobeNewswire 5 months ago

ORGS
0.00%
Orgenesis Commences Trading on OTCQX® Best Market

Reports Plans to Reapply for Nasdaq Listing Announces Progress Advancing Decentralized Cell Processing Platform GERMANTOWN, Md., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today announced that its common stock will begin trading on the OTCQX® Best Market under the ticker symbol "ORGS" following i

GlobeNewswire 6 months ago

ORGS
0.00%
Orgenesis Announces Reverse Stock Split

GERMANTOWN, Md., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”) today announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company’s common stock, par value $0.0001, which will be effective at 5:00 pm Eastern Time on September 24, 2024. The Company’s common stock will continue to be traded on The Nasdaq Capital Market on a split-adjusted basis beginning on September 25, 2024, under the Company’s existing trading

GlobeNewswire 7 months ago

ORGS
0.00%
Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia

Orgenesis’ CD19 CAR-T therapy, ORG-101, had a complete response (CR) of 82% in adults and 93% in pediatric patients with the incidence of severe Cytokine Release Syndrome (CRS) of 2% in adult patients and 6% in pediatric patients in a real-world study Data indicate a potentially favorable safety profile with a lower incidence of Cytokine Release Syndrome Encouraged by the positive data, Harley Street Healthcare Group along with its partners intends to commit resources to set up a Global Cancer I

GlobeNewswire 7 months ago

ORGS
0.00%
Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally

The strategic alliance aims to drive new-age innovation in wellness & longevity, backed by an investment commitment of up to $10 million over 3 years into both Orgenesis and the newly formed joint ventureGERMANTOWN, Md., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today announced a strategic partn

GlobeNewswire 8 months ago

ORGS
0.00%
Orgenesis Provides Second Quarter 2024 Business Update

Acquired GMP-validated platforms for launching proprietary CAR-T, tumor-infiltrating lymphocytes, lentivirus vectors, oncolytic virus cell carriers, and therapeutic exosomesGERMANTOWN, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today provided a business update for the second quarter ended Ju

GlobeNewswire 8 months ago

ORGS
0.00%
Orgenesis Provides Business Update for the First Quarter of 2024

Accelerates rollout of POCare platform following partnership agreement with Germfree and acquisition regaining full ownership and control over OctomeraGERMANTOWN, Md., May 21, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today provided a business update for the first quarter ended March 31, 2024. Vered Capl

GlobeNewswire 11 months ago

ORGS
0.00%

Performance Overview

Return	ORGS	S&P 500 (^GSPC)
YTD	+14.81%	-4.72%
1-Year	-59.06%	+11.67%
3-Year	-92.77%	+35.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Orgenesis Inc. (ORGS)

Orgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening its Regenerative Medicine Portfolio with Spinal Cord Injury Therapies

Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings

Orgenesis Provides Third Quarter 2024 Business Update

Orgenesis Commences Trading on OTCQX® Best Market

Orgenesis Announces Reverse Stock Split

Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia

Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally

Orgenesis Provides Second Quarter 2024 Business Update

Orgenesis Provides Business Update for the First Quarter of 2024

Performance Overview